Related Experiment Videos

A dose-response analysis of candesartan-hydrochlorothiazide combination therapy in patients with hypertension

Björn Wilgot Karlson1, Sofia Zetterstrand, Bertil Olofsson

  • 1AstraZeneca R&D, Mölndal, Sweden. bjorn.w.karlson@astrazeneca.com

Blood Pressure
|May 23, 2009
PubMed

Insights

The combination of candesartan and hydrochlorothiazide (HCT) effectively lowers blood pressure in a dose-dependent manner. The effects of both drugs are additive, offering flexible dosing options for hypertension management.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Clinical Hypertension

Background:

  • Hypertension is a major risk factor for cardiovascular disease.
  • Combination therapy is often necessary for effective blood pressure control.
  • Understanding dose-response relationships is crucial for optimizing treatment.

Purpose of the Study:

  • To characterize the antihypertensive dose-response of candesartan and hydrochlorothiazide (HCT) combination therapy.
  • To evaluate the additive effects of candesartan and HCT in lowering blood pressure.

Main Methods:

  • Analysis of data from 4632 patients with mild to moderate hypertension.
  • Utilized data from seven randomized, double-blind, placebo-controlled studies.
  • Employed an Emax model to determine placebo-adjusted dose-response for systolic and diastolic blood pressure reduction.

Main Results:

  • Blood pressure reduction increased with escalating doses of candesartan and HCT.
  • Systolic blood pressure reduction ranged from 5.9 to 17.4 mmHg; diastolic reduction ranged from 2.8 to 10.2 mmHg.
  • The effects of candesartan and HCT were found to be fully additive.

Conclusions:

  • Candesartan-HCT combination therapy demonstrates a dose-related antihypertensive effect across a broad dosage range.
  • The additive nature of the components allows for tailored dosing strategies.
  • Findings provide valuable guidance for clinical hypertension management using this combination.
Abstract

Related Concept Videos

Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...